

Phenotypic Detection Of Carbapenemase Production Among *Klebsiella* Spp From Clinical Samples From A Tertiary Care Hospital

Dr Rishi Dhurve¹, Dr Manish Purohit^{2*}, Dr Anita Mutha³

¹Ex PG Dept of Microbiology, MGMMC, Indore

^{2*}Associate Prof Microbiology, MGMMC, Indore

³Professor, Microbiology, MGMMC, Indore

***Corresponding Author:** Dr Manish Purohit

*Associate Prof, Microbiology, MGMMC, Indore, Email: mainshpurohit75@yahoo.co.in

Abstract:

Carbapenemase produced by *Klebsiella pneumoniae* can confer resistance to all β -lactam agents including carbapenems. The enzyme may develop low-level carbapenem resistance, leads to failure of routine antimicrobial susceptibility testing methods to identify this mechanism of resistance. Automated and nonautomated methods for carbapenem susceptibility were evaluated by various studies. In our study a total of 160 isolates of *Klebsiella* were isolated from various clinical specimens. Out of 160, 101(63.1%) showed resistance to carbapenem tested in study and was considered screen test positive. On confirmation of Carbapenemase production by Modified Hodge test, Modified Carbapenem Inactivation(mCIM) method and EDTA –Modified Carbapenem inactivation method(eCIM), 76.2%, 92.1% and 92.1% isolates showed production of carbapenemase respectively .

Keywords: Antibiotic, Carbapenem, *Klebsiella*

Introduction:

Emergence of resistance to carbapenem antibiotics has been increased recently among clinical isolates of *Klebsiella pneumoniae*. Production of carbapenem-hydrolyzing enzyme is one of the major resistance mechanisms to this group of antibiotics(1). Carbapenems are one of the most important broad-spectrum β -lactam antibiotics and have greater activity against many resistant bacteria such as those which have the ability to produce AmpC β -lactamase. Across the globe, first reports of Carbapenemases occurred in the 1980s. Its subsequent spread raised a number of concerns, and these have coincided with years in which no new antimicrobial agents against Gram-negatives have been developed. Japan reported the first Carbapenemase from an *Aeromonas hydrophila* isolate in the 1980s. Sequentially, followed in London (1982) by Seoul imipenemase(SME-1) from *Serratia marcescens*, imipenemases(IMI-1) in California (1984) and NMC-A in France (1990) ,both from *Enterobacter cloacae*. Carbapenems members of β -lactam family of antimicrobials that are structurally related to the Penicillins. Mechanism of action in carbapenems is initiated first by penetrating the bacterial cell wall and binding to enzymes known as penicillin-binding proteins (PBPs). The inhibiting series of PBPs are 1a, 1b, 2 and 3; and the resultant lethal effect, the inactivation of an inhibitor of autolytic enzymes within the cell wall which leads to killing of bacteria.^{8-11} In India it has been reported that 65.4% isolates were ESBL producers, 28.5% were AmpC producers, 9.4% were combined ESBL and AmpC producers and 48.6% were Carbapenemases producers in which 25.6% were KPC and 23% MBL producers and 8.2% were KPC and MBL coproducers. The presence of a carbapenemase can be detected by a

different method in clinical laboratories. These include automated systems or disc diffusion, MICs, selective agar, modified Hodge test, synergy tests (e.g., E-tests or double disc tests), spectrometry, genome sequencing and by molecular methods.

Performing antimicrobials susceptibility testing and resistance pattern identification plays an important role in treating patients since these isolates showing multidrug resistance are of great concern for the treating physician and it plays a significant role in the mortality of the patient. Hence, the current study was conducted to determine the most common *Klebsiella* species, antibiotic sensitivity pattern, diverse resistance mechanism among isolates for carbapenem resistance and Detection of MIC for colistin among Carbapenamase producing *Klebsiella* spp. Further Comparison of different methods for detection of Carbapenamase production was also done.

Aim:

Present study was aimed for Phenotypic detection of Carbapenamase production among *Klebsiella* spp. Isolated from clinical specimen from a tertiary care center of Central India.

MATERIAL&METHODS:

Study Design: Cross-sectional Observational Study.

Study Centre: The study was carried out in the Department of Microbiology, of a tertiary care hospital.

Duration Of the Study: Study duration was 1 year from 11 June 2021 to 10 June 2022 after the approval from the institutional ethics committee.

Sample Size: 500 isolates were taken out of which 160 isolates found to be *Klebsiella* spp.

Inclusion criteria: All *Klebsiella* spp. isolated from various specimen received for culture and sensitivity in Department of Microbiology.

Exclusion Criteria: Repeat isolate of *Klebsiella* spp. from same patient.

Methodology

All specimens received for culture and sensitivity were processed as per standard guidelines. Isolation and identification of *Klebsiella* spp. was done using Colony morphology, Gram staining and biochemical tests as per standard guidelines. Antimicrobial sensitivity testing of isolated *Klebsiella* spp was done using Kirby Bauer disc diffusion method as per CLSIM 1002022 guidelines[2].

Screening criteria for carbapenamase production: Organism which were found resistant to imipenem and/or Meropenem were considered as probable Carbapenamase producers.

Confirmation of Carbapenamase

Modified Hodge Test, Modified carbapenem inactivation method (mCIM), EDTA-modified carbapenem inactivation method (eCIM) was used to confirm carbapenamase production among screen positive *Klebsiella* spp.

Result and Discussion:

A total of 500 isolates from various clinical samples were taken for the study, out of which 160

clinically consecutive, nonduplicate, significant isolates of *Klebsiella spp* were isolated and included in the study. Out of 160

Klebsiella spp isolates 129 were obtained from the IPD and remaining 31 were from OPD. Number of *Klebsiella spp* isolated from various clinical samples were in following order: urine (61/38.1%), pus (53/33.1%), sputum (13/8.1%), bronchoalveolar (11/6.9%), ear swab (9/6.9%), throat swab (8/5%) and CSF (5/3.1%). In the current study majority of *Klebsiella spp* were isolated from urine cultures (38.1%). This observation is in accordance to that of PS Patil et al. [3] (29.7%), Leavitt et al. (2010), [4] Parveen et al. (2010) [5] Bashir et al. (2014) [6] and Vivan et al. (2017) [7] who reported maximum isolation of *K. Pneumoniae* from urine samples. Amongst the 160 isolates, 101 (63.1%) were found resistant to Imipenem and/or meropenem and considered to be screen positive (IPD: 82; OPD: 19) whereas 59 (36.9%) were screen negative (IPD: 47; OPD: 12). This was in concurrence with results obtained by Vamsi SK et al. [8] who reported that out of the 220 isolates, 207 (94.0%) had screen test positivity. Further, the results were also comparable to that reported by Diwakar et al. [9]

For confirmation of carbapenemase production among screen positive *Klebsiella spp.*, Modified Hodge test, MCIM and ECIM was done. ECIM and MCIM test showed similar sensitivity with 92 (91.1%) positives and 9 (8.9%) negatives. However, Modified Hodge test (MHT) showed 77 (76.2%) positives and 24 (23.8%) negatives. For ECIM positive outcome, i.e., 92 isolates; 100% concurrence was observed when cross checked by MHT test. However, for MHT positive outcomes i.e., 77 isolates; 98.7% (76) positive outcomes were observed when cross checked by mCIM test.

In the study of Amjad et al. (2011), [10] 17% of *K. pneumoniae* showed positive modified Hodge test. Anderson and colleagues at CDC evaluated 45 isolated by modified Hodge test and further validated by PCR for detection of Carbapenemase activity.¹⁰³ Modified Hodge test was found to be 100% sensitive and specific for detection of carbapenem resistance in *K. pneumoniae*. Bashir H et al. reported modified Hodge test as a reliable and sensitive laboratory method for detection of carbapenem. The treatment of *Klebsiella* infections remain a great challenge because resistant to aminoglycosides, cephalosporins and quinolones has substantially increased world wide.

Carbapenems are the drug of choice for MDR *Klebsiella* infections, for ESBL and AmpC producing isolates, but resistance to carbapenems by the production of carbapenemases and various other mechanisms has limited the therapeutic options.

Among total 160 *Klebsiella* isolates, 92 showed carbapenemase production it is about 57.5% whereas Carbapenemase production among screen test positive isolates was found to be 91.1% indicating need for continuous screening of all carbapenem resistant isolates. MCIM and ECIM test showed similar sensitivity with 92 (91.1%) positives and 9 (8.9%) negatives. However, Modified Hodge test (MHT) showed lower sensitivity with 77 (76.2%) positives and 24 (23.8%) negatives. Therefore, we can do MCIM testing among all MHT negative isolates to increase sensitivity of test.

Conclusion

The treatment of *Klebsiella* infections remain a great challenge because of multidrug resistant strains. Routine monitoring of Carbapenemase is need of hours so that appropriate and timely right treatment can be given. Simple and inexpensive method for detection of Carbapenemase will help in rapid and correct identification. So, updating ourselves, exploring new diagnostic options and implementing new testing strategies can help to detect these carbapenemase for early and proper patient management. Emergence of antimicrobial resistance in bacteria has serious effects like high morbidity and mortality rates, increased length of hospital stays and additional financial burden on patients.

Table 1. Sample Distribution on Basis of Location

Lab	Frequency	Percent
IPD	129	80.6
OPD	31	19.4
Total	160	100.0

Table2.Distribution on Basis of Screening for carbapenamase production

Screening Outcome	Frequency	Percent
Positive	101	63.1
Negative	59	36.9
Total	160	100.0

Chart-1.DistributiononBasisof Specimen





Image-1 Modified Hodge test



References

1. Topley and Wilson's Ninth edition "Systemic Bacteriology" Volume 2 Volume editors Albert Balows, Brian I Chapter 57 klebsiella by R R Facklam and L M Teixeira pages 1474-1482.
2. CLSI. Performance Standards for Antimicrobial Susceptibility Testing, Twentieth Informational Supplement, CLSI Document M100-S20, Wayne, PA: Clinical and Laboratory Standards Institute, 2022

3. PS Patil et al. Phenotypic Detection of Carbapenem Resistance in Clinical Isolate of *Klebsiella Pneumoniae* in Tertiary Care Hospital. Journal of Pharmaceutical Negative Results | Volume 13 | Special Issue 8 | 2022
4. Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S. Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing *Klebsiella pneumoniae* strains in Israel. *Antimicrob Agents Chemother.* 2010;54:3002-3006
5. Parveen RM, Harish BN, Parija SC. Emerging carbapenem resistance among nosocomial isolates of *Klebsiella pneumoniae* in South India. *Int J Pharma Bio Sci.* 2010;1:1-11.
6. Bashir H, Kakru D, Qadri S, Bali N, Bashir S, Lone S. Carbapenem-resistant *Klebsiella pneumoniae* in a tertiary care Hospital in Northern India. *International Journal.* 2014;2:92-102
7. Vivan A, Rosa J, Rizek C, Pelisson M, Costa S, Hungria M, et al. Molecular characterization of carbapenem-resistant *Klebsiella pneumoniae* isolates from a university hospital in Brazil. *Embrapa Soja-Artigo em periódico indexado (ALICE).* 2017
8. Vamsi SK, Moorthy RS, Hemilamma MN, Chandra Reddy RB, Chanderakant DJ, Sirikonda S. Phenotypic and genotypic detection of carbapenemase production among gram negative bacteria isolated from hospital acquired infections. *Saudi Med J.* 2022 Mar;43(3):236-243. doi:10.15537/smj.2022.43..20210809. PMID: 35256490; PMCID: PMC9280532.
9. Diwakar J, Verma RK, Singh DP, Singh A, Kumari S. Phenotypic detection of carbapenem resistance in Gram-negative bacilli from various clinical specimens of a tertiary care hospital in Western Uttar Pradesh. *Int J Res Med Sci* 2017; 5: 3511–3514.
10. Amjad A, Mirza IA, Abbasi SA, Farwa U, Malik N, Zia F. Modified Hodge test: A simple and effective test for detection of carbapenemase production. *Iranian Journal of Microbiology.* 2011;3(4):189.